Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 0.32 | uM | 12084.145 | 0.9672 | 0.9438 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 1.6 | uM | 12084.145 | 0.9956 | 0.9925 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 8 | uM | 12084.145 | 0.8348 | 0.7137 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 40 | uM | 12084.145 | 0.8739 | 0.7822 | 1.1692 | |
| HCC1395 | TNBC | Basal B | Nilotinib | ABL | nRTK | 200 | uM | 12084.145 | 0.8537 | 0.7469 | 1.1692 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 10693.145 | 1.0117 | 1.0277 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 10693.145 | 0.9549 | 0.8943 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 10693.145 | 1.0150 | 1.0354 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 10693.145 | 0.9970 | 0.9929 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 10693.145 | 1.0366 | 1.0864 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 10693.145 | 0.9781 | 0.9485 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 10693.145 | 0.9269 | 0.8289 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 10693.145 | 0.6486 | 0.2012 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 10693.145 | 0.8187 | 0.5802 | 0.8492 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.000512 | uM | 11936.145 | 1.0028 | 1.0066 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.00256 | uM | 11936.145 | 0.9510 | 0.8846 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.0128 | uM | 11936.145 | 1.0592 | 1.1410 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.064 | uM | 11936.145 | 0.9951 | 0.9884 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 0.32 | uM | 11936.145 | 0.9565 | 0.8975 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 1.6 | uM | 11936.145 | 0.9657 | 0.9190 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 8 | uM | 11936.145 | 0.7745 | 0.4781 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 40 | uM | 11936.145 | 0.8400 | 0.6271 | 0.8451 | |
| HCC1428 | HR+ | Luminal | Nilotinib | ABL | nRTK | 200 | uM | 11936.145 | 0.7862 | 0.5045 | 0.8451 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.000512 | uM | 10872.145 | 0.9889 | 0.9864 | 1.6308 | |
| HCC1569 | HER2amp | Basal A | Nilotinib | ABL | nRTK | 0.00256 | uM | 10872.145 | 0.9613 | 0.9522 | 1.6308 |